FAQ: Quantum BioPharma's Lucid-MS IND Application and Corporate Overview
Summary
Quantum BioPharma has received final toxicity reports for Lucid-MS, supporting its upcoming IND application to the FDA for a Phase 2 clinical trial targeting multiple sclerosis treatment.
What is the main announcement from Quantum BioPharma?
Quantum BioPharma has received final reports from its 90-day oral toxicity and toxicokinetic studies for Lucid-MS, which will support the company’s upcoming IND application to the U.S. FDA for a Phase 2 clinical trial.
What is Lucid-MS and what does it treat?
Lucid-MS is Quantum BioPharma’s potential breakthrough drug for Multiple Sclerosis, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
Why is this development significant for Quantum BioPharma?
This marks a key milestone in advancing Lucid-MS as a first-in-class treatment targeting demyelination in MS patients, moving the drug closer to Phase 2 clinical trials.
What is Quantum BioPharma’s primary focus as a company?
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development.
How is Lucid-MS developed within the company structure?
Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS.
What other business interests does Quantum BioPharma maintain?
Quantum BioPharma invented unbuzzd™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining 20.11% ownership and royalty payments, plus maintains strategic investments through its subsidiary FSD Strategic Investments Inc.
Where can investors find more information about Quantum BioPharma?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
What are the next steps for Lucid-MS following these toxicity reports?
The company will submit an IND application to the U.S. FDA to seek approval for a Phase 2 clinical trial of Lucid-MS for multiple sclerosis treatment.
What makes Lucid-MS unique as a potential MS treatment?
Lucid-MS is positioned as a first-in-class treatment that targets demyelination, the underlying mechanism of multiple sclerosis, representing a novel approach to treating the disease.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 241526